HQL offers a high 12% yield and trades at a discount, making it attractive for income-focused investors seeking healthcare sector exposure. The fund is heavily weighted in biotechnology, leading to ...
abrdn Life Sciences Investors Fund maintains a buy rating, offering a compelling 11.6% yield and trading at a 9.58% NAV discount. HQL’s income-focused strategy relies on net realized gains, supporting ...
Explore abrdn Life Sciences stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for HQL.
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
PHILADELPHIA, PA / ACCESSWIRE / May 9, 2024 / abrdn Life Sciences Investors (HQL) and abrdn Healthcare Investors (HQH), (collectively, the "Funds") each, a closed-end management investment company, ...
$HQL insiders have traded $HQL stock on the open market 8 times in the past 6 months. Of those trades, 1 have been purchases and 7 have been sales. Here’s a ...
PHILADELPHIA, PA / ACCESSWIRE / January 10, 2025 / The abrdn U.S. Closed-End Funds (NYSE:ASGI, HQH, HQL, IFN, JEQ, THQ)(NYSE American:IAF) (the "Funds" or individually the "Fund"), today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results